Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.49 USD | -1.65% | -3.19% | +9.70% |
May. 21 | Avadel Pharmaceuticals plc Appoints Naseem Amin to Its Board of Directors | CI |
May. 14 | European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading | MT |
Valuation
Fiscal Period: December | 2024 | 2025 | 2026 |
---|---|---|---|
Capitalization 1 | 1,489 | - | - |
Enterprise Value (EV) 1 | 1,469 | 1,419 | 1,296 |
P/E ratio | -28 x | 25.9 x | 9.29 x |
Yield | - | - | - |
Capitalization / Revenue | 8.85 x | 4.97 x | 3.72 x |
EV / Revenue | 8.73 x | 4.74 x | 3.24 x |
EV / EBITDA | 1,171 x | 6.53 x | 4.95 x |
EV / FCF | 91.8 x | 13.9 x | 6.86 x |
FCF Yield | 1.09% | 7.19% | 14.6% |
Price to Book | 22.7 x | 9.77 x | 4.24 x |
Nbr of stocks (in thousands) | 96,119 | - | - |
Reference price 2 | 15.49 | 15.49 | 15.49 |
Announcement Date | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 59.22 | 22.33 | - | - | 27.96 | 168.3 | 299.4 | 400.2 |
EBITDA 1 | - | - | - | - | -136.1 | 1.255 | 217.1 | 261.5 |
EBIT 1 | -24.11 | 5.815 | -85.55 | -98.56 | -137.8 | -46.8 | 57.32 | 164.4 |
Operating Margin | -40.72% | 26.04% | - | - | -492.97% | -27.8% | 19.15% | 41.09% |
Earnings before Tax (EBT) 1 | -38.58 | -5.082 | -93.14 | -111.4 | -160.8 | -50.67 | 52.33 | 160.1 |
Net income 1 | -33.23 | 7.028 | -77.33 | -137.5 | -160.3 | -48.45 | 58.56 | 166.5 |
Net margin | -56.11% | 31.47% | - | - | -573.17% | -28.79% | 19.56% | 41.6% |
EPS 2 | - | - | - | - | - | -0.5533 | 0.5986 | 1.668 |
Free Cash Flow 1 | - | -48.83 | -77.34 | -71.02 | - | 16 | 102 | 189 |
FCF margin | - | -218.64% | - | - | - | 9.51% | 34.07% | 47.23% |
FCF Conversion (EBITDA) | - | - | - | - | - | 1,274.86% | 46.98% | 72.27% |
FCF Conversion (Net income) | - | - | - | - | - | - | 174.18% | 113.53% |
Dividend per Share 2 | - | - | - | - | - | - | - | - |
Announcement Date | 3/12/20 | 3/9/21 | 3/16/22 | 3/29/23 | 2/29/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | 1.496 | 7.014 | 19.45 | 27.18 | 37.58 | 47.37 | 56.18 | 61.14 | 68.68 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -23.14 | -28.63 | -26.34 | -16.96 | -23.04 | -28.3 | -49.54 | -35.11 | -24.9 | -26.04 | -15.58 | -6.98 | 1.783 | 1.576 | 8.366 |
Operating Margin | - | - | - | - | - | - | -3,311.56% | -500.57% | -128% | -95.79% | -41.47% | -14.73% | 3.17% | 2.58% | 12.18% |
Earnings before Tax (EBT) 1 | -26.64 | -30.75 | -33.25 | -20.08 | -27.36 | -31.36 | -64.34 | -36.18 | -28.89 | -27.25 | -16.29 | -7.852 | 0.7354 | 0.2882 | 6.953 |
Net income 1 | -22.3 | -26.42 | -63.44 | -20.15 | -27.45 | -30.78 | -64.43 | -36.27 | -28.79 | -27.34 | -15.82 | -7.128 | 1.409 | 0.2882 | 6.828 |
Net margin | - | - | - | - | - | - | -4,306.95% | -517.17% | -147.98% | -100.6% | -42.09% | -15.05% | 2.51% | 0.47% | 9.94% |
EPS 2 | - | - | - | - | - | - | - | - | - | - | -0.1744 | -0.0800 | 0.0112 | 0.005000 | 0.0725 |
Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/16/22 | 5/9/22 | 8/9/22 | 11/9/22 | 3/29/23 | 5/4/23 | 8/9/23 | 11/8/23 | 2/29/24 | 5/8/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | 57.5 | - | - | 32.8 | - | - | - | - |
Net Cash position 1 | - | 93.2 | 13.9 | - | 72.4 | 19.7 | 70.2 | 193 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | -48.8 | -77.3 | -71 | - | 16 | 102 | 189 |
ROE (net income / shareholders' equity) | - | - | - | - | - | -8.23% | 165% | 126% |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share 2 | - | - | - | - | - | 0.6800 | 1.590 | 3.650 |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex 1 | 0.03 | 0.1 | 0.03 | 0.72 | - | 4.81 | 9.1 | 12.2 |
Capex / Sales | 0.05% | 0.44% | - | - | - | 2.86% | 3.04% | 3.04% |
Announcement Date | 3/12/20 | 3/9/21 | 3/16/22 | 3/29/23 | 2/29/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.70% | 1.49B | |
+38.59% | 727B | |
-7.89% | 347B | |
+15.66% | 319B | |
+0.24% | 274B | |
+13.21% | 238B | |
+7.22% | 204B | |
-6.18% | 203B | |
+4.23% | 161B | |
-1.70% | 160B |
- Stock Market
- Equities
- AVDL Stock
- Financials Avadel Pharmaceuticals plc